Table 1.
Study characteristics.
| First Author, Year, Country [Ref] | Matrix | n | Age (yrs) |
M/F | GPx Bas Mean ± SD |
GPx Post Mean ± SD |
SOD Bas Mean ± SD |
SOD Post Mean ± SD |
Cat Bas Mean ± SD |
Cat Post Mean ± SD |
Condition | Statin and Daily Dose | Treatment (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chen MF, 1997, Taiwan [46] | P | 20 | 47 | 11/9 | 0.98 ± 0.32 U/mL | 1.08 ± 0.29 U/mL | NR | NR | NR | NR | HCL | Pravastatin 5 mg | 12 |
| Yilmaz MI, 2004, Turkey [27] | E | 35 | 48 | 18/17 | 20.93 ± 10.46 U/mL | 39.13 ± 6.76 U/mL | 510 ± 190 U/mL | 589 ± 182 U/mL | NR | NR | HCL | Fluvastatin 40 mg | 12 |
| Ghayour-Mobarhan M, 1997, UK [47] | S | 11 | 52 | 7/4 | 0.36 ± 0.13 U/mL | 0.32 ± 0.13 U/mL | NR | NR | NR | NR | HCL | Simvastatin 10 mg | 16 |
| Molčányiová A, 2006, Slovakia [48] | E | 42 | 60 | 12/30 | 6.03 ± 2.97 U/mL | 9.67 ± 4.27 U/mL | NR | NR | NR | NR | HCL | Simvastatin 20 mg | 8 |
| Ruiz MC, 2006, Spain [49] | S | 21 | NR | NR | 74 ± 22 nmol/mg | 106 ± 22 nmol/mg | 170 ± 49 U/mg | 181 ± 31 U/mg | 7.48 ± 0.84 KU × 10−5/mg |
7.59 ± 1.38 KU × 10−5/mg |
Kidney Tx | Atorvastatin 10–40 mg | 24 |
| Save V, 2006, India [50] | E | 100 | 51 | 29/71 | 1.2 ± 0.2 U/mL | 1.1 ± 0.2 U/mL | 3673 ± 369 U/gHb | 6260 ± 375 U/gHb | NR | NR | T2D | Atorvastatin 10 mg | 24 |
| Su Y, 2010 (a), China [51] | E | 75 | 55 | 39/36 | 18.96 ± 1.45 µmol/L | 21.57 ± 1.63 µmol/L | 65.73 ± 17.02 mmol/L | 96.54 ± 17.34 mmol/L | NR | NR | T2D | Simvastatin 40 mg | 12 |
| Su Y, 2010 (b), China [51] | E | 76 | 56 | 43/33 | 17.31 ± 1.11 µmol/L | 21.28 ± 0.57 µmol/L | 75.15 ± 13.31 mmol/L | 100.23 ± 15.67 mmol/L | NR | NR | T2D | Atorvastatin 10 mg | 12 |
| Janic M, 2014, Slovenia [52] | WB | 25 | 44 | 25/0 | 1.10 ± 0.25 U/gHb | 1.14 ± 0.20 U/gHb | NR | NR | NR | NR | Healthy | Fluvastatin 10 mg | 4.5 |
| Sena-Evangelista KCM, 2015, Brazil [53] | WB | 38 | 63 | 23/15 | 41.33 ± 9.62 U/gHb | 44.67 ± 13.33 U/gHb | 1415 ± 340 U/gHg | 1468 ± 265 U/gHg | NR | NR | CAD | Rosuvastatin 10 mg | 16 |
| Yildiz A, 2015, Turkey [54] | E | 18 | 38 | 9/9 | 22.37 ± 7.99 U/gHb | 30.7 ± 13.4 U/gHb | 19.09 ± 4.61 U/gHg | 24.34 ± 7.99 U/gHg | NR | NR | Kidney Tx | Fluvastatin 80 mg | 4 |
| Fassett RG, 2015, Australia [55] | P | 47 | 65 | 28/19 | 32.8 ± 10.1 U/L | 31.4 ± 11.1 U/L | NR | NR | NR | NR | CKD | Atorvastatin 10 mg | 3 years |
| Hernandez-Mijares A, 2016, Spain [56] | S | 20 | 58 | 5/15 | NR | NR | 0.81 ± 0.14 U/mL | 0.92 ± 0.18 U/mL | 29.4 ± 17.9 U/mL | 28.1 ± 13.0 U/mL | HCL | Simvastatin 40 mg | 4 |
| Abdel Magid AM, 2017, Egypt [57] | S | 30 | 51 | 15/15 | 98 ± 78 U/L | 142 ± 133 U/L | NR | NR | NR | NR | HD | Simvastatin 60 mg * | 16 |
| Hadzi-Petrushev N, 2018, Macedonia [58] | S | 20 | 43 | 20/0 | 277 ± 85 U/mL | 223 ± 95 U/mL | NR | NR | 85 ± 36 U/mL | 64 ± 47 U/mL | NAFLD | Atorvastatin 20 mg | 12 |
| Mayyas F, 2018 (a), Jordan [59] | P | 122 | 51 | 81/41 | NR | NR | 28 ± 6 U/mL | 69 ± 44 U/mL | NR | NR | ASCVD | Atorvastatin 20 mg | 12 |
| Mayyas F, 2018 (b), Jordan [59] | P | 37 | 51 | 24/13 | NR | NR | 30 ± 18 U/mL | 75 ± 43 U/mL | NR | NR | ASCVD | Atorvastatin 40 mg | 12 |
Legend: P, plasma; S, serum; E, erythrocytes; WB, whole blood; GPx, glutathione peroxidase; SOD, superoxide dismutase; Cat, catalase; HCL, hypercholesterolemia; Tx, transplant; T2D, type 2 diabetes; CAD, coronary artery disease; CKD, chronic kidney disease; HD, haemodialysis; NAFLD, non-alcoholic fatty liver disease; ASCVD, atherosclerotic cardiovascular disease; NR, not reported; *, weekly.